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of N2 disease should be confirmed by surgical pathologic
evaluation.
A high SUV in the primary tumor seems to correlate with
the presence of mediastinal nodal metastasis. This may
simply reflect the propensity of more metabolically active
tumors to metastasize to mediastinal nodes. This is an
interesting preliminary finding. Further investigation is
needed to determine if there is a specific SUV level at which
mediastinal nodal metastasis is likely to be present. Such
information may be of potential use in selecting patients for
surgical resection.
Our data indicate that FDG PET may be useful in iden-
tifying extrathoracic disease either preoperatively or in the
setting of potential tumor recurrence. Although these find-
ings warrant confirmation in a larger number of patients, it
is valuable to identify even a small number of patients in
whom surgical intervention may be inappropriate.
This experience builds on that reported in previous stud-
ies. The number of patients in our study is larger than in
previously published studies, but it is still a somewhat
heterogenous patient cohort. Additional studies in still
larger numbers of patients are warranted. Future studies
should investigate our observation that high primary tumor
SUV correlates with N2 disease and could validate the lack
of correlation between SUV and histologic subtype. Inves-
tigations of the accuracy of combined PET/CT scanning
should also be undertaken to determine whether this imag-
ing modality leads to better definition of T and N status.
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Discussion
Dr David J. Sugarbaker (Boston, Mass). I very much appre-
ciated the opportunity to read the article by Dr Flores and his group
at Memorial regarding this interesting study of PET and mesothe-
lioma. I think it is important to look for different modalities to
understand preoperatively the extent of disease in mesothelioma,
and I suggest that the findings in this particular study are not
unexpected. The difficulty of defining the preoperative stage in
mesothelioma is derived from the fact that the geographical dis-
tribution of the tumor, unlike other malignancies, is very diffuse,
and all of the modalities, including MRI and CT scan (which
preceded PET), have had difficulty in defining preoperatively the
appropriate stage. Nevertheless, this study suggests that there are
some limited useful applications of PET in mesothelioma, partic-
ularly in those malignancies that have a high metabolic rate taking
up a lot of the markers; thus, there is the implication of a very high
mitotic index and therefore a higher propensity to spread to the
lymph nodes. Unfortunately, there is a very small group of patients
who will demonstrate distant metastatic disease at the time of
presentation. Nevertheless, in this small group of patients, it seems
that PET has some usefulness.
I have 3 questions for Dr Flores and his group at Memorial,
who obviously have extensive experience with mesothelioma.
First, I believe 21 patients in your series were “open and close,”
unresectable. Given the limited cohort you had, this seems to be a
relatively high unresectability rate. Would you address that and tell
us if there was anything in the MRI, CT, or other aspects of the
preoperative workup that may have indicated that these patients
were indeed unresectable before their exploration? As a sideline to
that question, was there a propensity for these patients to be mixed
or sarcomatous types as opposed to epithelial types?
My second question concerns your statement that MRI is
unreliable in determining resectability. Some years ago at
Brigham, I, Dr Patz, and some of our colleagues in radiology wrote
about the fact that although MRI is somewhat limited, it is the most
useful preoperative staging radiologic modality when coupled with
echocardiography. This is primarily because MRI allows one to
see 2 important areas more easily and accurately than CT scan-
ning: transdiaphragmatic extension of the disease and transmedi-
astinal invasion into structures that are clearly going to render the
patient unresectable. So, I ask you to comment on your use of MRI
and echocardiography at Memorial in the workup of these patients.
Third, would you comment on the presence or absence of chest
pain in your patients who are unresectable? What is your use of
mediastinoscopy in the preoperative workup of these patients? We
have found that even mild chest pain is often the best predictor of
diffuse chest wall invasion by these tumors.
I thank Dr Flores and his group and congratulate them on an
excellent study, which I think contributes to our knowledge of
mesothelioma and to our understanding of the use of PET scanning
in this disease.
Dr Flores. I will start by combining the first and third ques-
tions. In regard to the unresectability rate, many PET scans per-
formed in patients were not obtained uniformly. Initially, more
PET scans were performed in patients who had a higher tumor
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bulk on CT; thus, theoretically, they may have had a higher
incidence of unresectability. This was an inhomogeneous group of
patients. Not every single patient underwent PET scanning, and I
do have to say that the study was biased toward the patients who
had a higher indication of unresectability on CAT scan.
When patients experienced chest pain, it indicated the necessity
for a PET scan; however, the scan was not uniformly obtained by
every surgeon. But, those patients who experienced chest pain did
tend to have PET scans performed.
Two patients with sarcoma in this series were found to have T4
lesions. In regard to MRI, I am very aware of the article written by
you and your colleagues demonstrating the usefulness of MRI.
There was also another article written by investigators at our
institution (Dr Hellan was the first author) that basically compared
MRI and CT scan, and although MRI did have a higher rate of
diagnosing (eg, as you stated, transdiaphragmatic invasion), this
was not found to be a clinically significant finding as far as
changing the preoperative management of the patient. Thus, al-
though MRI may be sensitive in certain areas, it does not change
the decision to take the patient to the OR.
Our experience at Memorial demonstrates that echocardiogra-
phy is not helpful in these patients, and we usually obtain cardiac
sestamibi stress tests instead. Because of the magnitude of the
operation, we look more for cardiovascular disease rather than
pericardial effusions. We do not routinely perform mediastinos-
copy, but I do think that needs to be studied.
Dr D. Miller (Atlanta, Ga). I would echo your thoughts. In
regard to PET, it is not very accurate within the mediastinum, but
it has helped tremendously for distant metastasis. At the Mayo
Clinic, we routinely proceed with a mediastinoscopy before an
extrapleural pneumonectomy. However, in several operations, per-
formed after a preoperative PET scan that showed no nodal in-
volvement, on entering the chest, we found N2 nodal involvement
at the paraesophageal or the inferior pulmonary ligament nodes,
which correlates more with lower chest disease. Where were the
N2 nodes located in your 8 patients with N2 involvement? Were
those nodes actually located in the inferior mediastinum, which
could have been overshadowed by the SUV activity from the
mesothelioma at the pleuropericardial junction, or were they even
higher (up around the paratracheal and so forth)? Several times in
operations, we found that patients already had N2 disease in a
lower location (we also investigated the possibility of EUS, but
then you run into the difficulty of having a false-positive result
because of the pleural disease, and so forth).
Dr Flores. All of these patients had level 7 nodes.
Dr W. R. Smythe (Houston, Tex). I enjoyed your article very
much. I have 2 comments about the use of PET in these patients
and 2 questions for you as well.
One of the problems with PET (and one of the idiosyncratic
things about mesothelioma) is that when performing mediastinos-
copy, one can find patients who have minimally or no enlarged
lymph nodes, but every node station is positive. In addition, as you
know, another problem with PET is that tumors of 5 mm or less are
below the resolution of most machines.
Second, in ipsilateral nodal disease, there is the problem of the
pleura abutting the nodes, and when one evaluates these scans, it
is very difficult (because of the lack of anatomic definition) to
determine with any degree of accuracy what is pleura and what is
node, especially when the mediastinal tumor is thick. CT-PET may
eventually be helpful here.
I have 2 questions. Medicare (and many third-party payers)
does not routinely pay for PET scanning for mesothelioma as a
staging test. I would be interested to know who paid for these 63
PET scans in your retrospective evaluation.
In addition, one of the major problems that we have after
resection of these patients is radiographically determining early
disease when it recurs. PET actually may play an important role
here. You mentioned that you performed PET scans on a few
patients in the postoperative period; do you plan to use this as a
routine follow-up modality?
Dr Flores. As far as the first question is concerned, I do not
know who pays for the PET scans.
Second, I believe that follow-up is useful in these patients if
you would consider resecting the areas that have positive results or
administering chemotherapy that would actually work in this dis-
ease. If we find lesions (eg, supraclavicular lymph node) in pa-
tients, we administer gemcitabine and cisplatin. I believe that
finding recurrent mesothelioma in these patients is dependent on
the type of treatment that you give them afterward.
Dr E. Vallieres (Seattle, Wash). Did any of your patients
receive a chemical pleurodesis of some sort, talc or other agent,
before their PET scan, and, if so, how long before? As we know,
that could potentially create a significant inflammatory reaction
and may result in higher SUV measurements that the tumor itself
would not give. Along the same line, did any of your patients
receive induction chemotherapy between the time of their PET
scan and the actual exploration and thoracotomy? This could also
have had some influence on the findings at surgery.
I appreciated your presentation and all the comments from the
previous discussants.
Dr Flores. Eighteen of these patients did have talc pleurodesis.
The shortest time period was 1 month before PET scan. This is a
confounding variable that we cannot control for with this study.
You are right, talc does cause an increase in the uptake on PET
scan, but we do not have that data.
Ten patients in this study received induction chemotherapy;
however, correlation with PET scan preinduction and postinduc-
tion therapy was not performed.
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